Skip to content

Author

Jonathan A. Ledermann

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Biomarker-Driven Treatments for Ovarian Cancer: Moving Beyond HRD?

Abstract Ovarian cancer is a biologically heterogeneous disease, yet for more than two decades its standard treatment of surgery and platinum–taxane chemotherapy changed little. Only a modest additional benefit was seen with the addition of bevacizumab, a monoclonal antibody targeting vascular endothelial growth factor...

Liz Joseph, Michael J. Flynn, Jonathan A. Ledermann · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.